CX3CL1 and neoplasm: In a non-CAR model of ACT, enhanced chemokine ligand / receptor matching was demonstrated using adoptively transferred T-cells engineered to express CX3CR1 (the fractalkine receptor), leading to enhanced homing towards CX3CL1-producing tumours and improved efficacy in an immunodeficient mouse xenograft model [211].